Climb Bio, Inc.
CLYM
$16.33
$1.6010.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.63% | 11.22% | 37.57% | 53.25% | 108.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.23% | 27.78% | 151.39% | 149.46% | 240.66% |
| Operating Income | -22.23% | -27.78% | -151.39% | -149.46% | -240.66% |
| Income Before Tax | -23.24% | 43.22% | 19.01% | 26.58% | 27.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.24% | 43.22% | 19.01% | 26.58% | 27.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.24% | 43.22% | 19.01% | 26.58% | 27.16% |
| EBIT | -22.23% | -27.78% | -151.39% | -149.46% | -240.66% |
| EBITDA | -506.38% | -- | -- | -- | -- |
| EPS Basic | -18.46% | 67.26% | 58.47% | 64.60% | 67.47% |
| Normalized Basic EPS | -27.97% | -24.56% | -132.51% | -58.29% | -43.71% |
| EPS Diluted | -18.46% | 67.26% | 58.47% | 64.60% | 67.47% |
| Normalized Diluted EPS | -27.97% | -24.56% | -132.51% | -58.29% | -43.71% |
| Average Basic Shares Outstanding | 4.85% | 18.12% | 42.52% | 75.55% | 136.95% |
| Average Diluted Shares Outstanding | 4.85% | 18.12% | 42.52% | 75.55% | 136.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |